GlassScriptPhysician profile
Pamela Beams
NPI 1750764221
$1,480.29
in general payments reported to CMS, 2019-2025
17 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2021: $59.49 · 2022: $118 · 2023: $229 · 2024: $513 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.82 |
| Education | $132.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $440.14 | 2022-2025 | Nucala |
| Genzyme Corporation | $266.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $220.86 | 2023-2024 | Dupixent |
| Medtronic USA, INC. | $121.86 | 2019 | |
| Intersect Ent, INC. | $59.49 | 2021 | |
| Spirair, INC. | $55.55 | 2025 | |
| Medtronic, INC. | $52.71 | 2024-2025 | Stealthstation S8 Platform, Sinuva, Pteye Parathyroid Detection System |
| Stryker Corporation | $41.63 | 2019 | |
| Merck Sharp & Dohme LLC | $34.99 | 2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $31.65 | 2024-2025 | Voquezna |
| Integra Lifesciences Corporation | $27.28 | 2023 | Integra, Integra Duo, Codman Isocool Aht |
| Allergan, INC. | $21.35 | 2022 | |
| Hikma Pharmaceuticals USA | $20.29 | 2025 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $20.23 | 2025 | Tezspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $15.69 | 2019 | |
| Neurent Medical Limited | $15.58 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Beams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.